Chugai Pharmaceutical vs Nanobiotix: A Comparative Review

Key Facts

Consensus price target for Nanobiotix: $37.33
Potential downside for Nanobiotix: 4.00%
Chugai Pharmaceutical beta: 0.6
Nanobiotix beta: 0.78
Institutional ownership: Chugai: 0.0%
Institutional ownership: Nanobiotix: 38.8%

Background

Chugai Pharmaceutical Co., Ltd., founded in 1925 and headquartered in Chuo, Japan, is a pharmaceutical company engaged in research, development, manufacture, and sale of pharmaceuticals in Japan and internationally. Its oncology products include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva. It also markets products for other diseases, including Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. The company operates as a subsidiary of Roche Holding Ltd.

Nanobiotix S.A., incorporated in 2003 and headquartered in Paris, France, is a clinical-stage biotechnology company focused on developing cancer treatments. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles, being studied for soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited for development and commercialization in Greater China, South Korea, Singapore, and Thailand.

Current Situation

According to a report by MarketBeat.com, analysts have set a consensus price target of $37.33 for Nanobiotix, suggesting a potential downside of 4.00%. The report states that analysts clearly believe Nanobiotix is more favorable than Chugai Pharmaceutical due to its higher possible upside.

Chugai Pharmaceutical has higher revenue and earnings than Nanobiotix. The comparison also covers net margins, return on equity, and return on assets. Chugai Pharmaceutical has a beta of 0.6, indicating its stock price is 40% less volatile than the S&P 500, while Nanobiotix has a beta of 0.78, indicating 22% less volatility.

Institutional ownership stands at 0.0% for Chugai Pharmaceutical and 38.8% for Nanobiotix. Additionally, 3.5% of Nanobiotix shares are held by company insiders. The report notes that strong institutional ownership is an indication that hedge funds, endowments, and large money managers believe a stock is poised for long-term growth. Overall, Chugai Pharmaceutical beats Nanobiotix on 7 of the 13 factors compared.

Comparison of Chugai Pharmaceutical and Nanobiotix
Metric	Chugai Pharmaceutical	Nanobiotix
Beta	0.6	0.78
Institutional Ownership	0.0%	38.8%
Insider Ownership	Not reported	3.5%
Consensus Price Target	Not reported	$37.33
Potential Downside	Not reported	4.00%

Data as reported by MarketBeat.com via tickerreport.com. 'Not reported' indicates the source did not provide a figure.

Impacts

Investors comparing the two healthcare companies may be influenced by the contrasting metrics. Chugai's higher revenue and earnings could appeal to those seeking established profitability, while Nanobiotix's higher institutional ownership (38.8%) and insider ownership (3.5%) might signal confidence from sophisticated investors despite its clinical-stage status.

The beta values indicate that both stocks are less volatile than the broader market, with Chugai being less volatile than Nanobiotix. This could affect risk-averse investors' decisions. However, the analyst consensus price target for Nanobiotix suggests a potential downside, which may temper expectations.

The comparison is based on 13 factors, with Chugai outperforming on 7. This suggests that while analysts may favor Nanobiotix's upside, Chugai holds advantages in several fundamental areas, potentially impacting investment choices depending on individual priorities.

Future Outlook

Scenario analysis: The possibilities below are not certain predictions.

If Nanobiotix's clinical programs, particularly NBTXR3, achieve regulatory successes, its stock could potentially rise, but the current consensus price target implies a possible decline of 4.00%. The outcome may depend on trial results and market conditions.

Chugai Pharmaceutical, with its established product portfolio and alliance with Roche, may continue to generate steady revenue and earnings. If it maintains its fundamental strengths, it could remain a stable investment, though its lack of institutional ownership might be a concern for some investors.

The comparative analysis could shift if either company releases new financial data, clinical updates, or changes in analyst ratings. Investors should monitor these developments to reassess the relative attractiveness of the two stocks.

Source: tickerreport.com

AMRIT EXPLAINER